DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Squamous Cell CarcinomaCarcinoma of Head/Neck
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-06-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00139230
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Drug: OSI-774 (Tarceva)
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 82
- Registration Number
- NCT00137800
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT00137852
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Avastin and Taxotere for Esophagogastric Cancer
- Conditions
- Esophageal CancerGastric Cancer
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 42
- Registration Number
- NCT00137813
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
- Conditions
- Mesothelioma
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2011-12-26
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT00137826
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Carcinoma
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT00137761
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors
- Conditions
- Neuroendocrine Tumors
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 34
- Registration Number
- NCT00137774
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
- Conditions
- Graft vs Host Disease
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00136396
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)
- Conditions
- Acute Myelogenous Leukemia
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00136448
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia
- Conditions
- Acute Myelogenous LeukemiaMyelodysplasia
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00136422
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States